Kezar Life Sciences Sells Sec61 Program for $1M Upfront, Up to $127M in Milestones

summarizeSummary

Kezar Life Sciences has sold its Sec61-based discovery and development program assets to Enodia Therapeutics for $1 million upfront, with potential for up to $127 million in milestone payments and royalties.

check_boxKey Events

• Asset Disposition

  Kezar Life Sciences entered into an asset purchase agreement with Enodia Therapeutics SAS, selling all rights, title, and interest in its Sec61-based discovery and development program assets, including product candidate KZR-261.

• Upfront Cash Payment

  The company received $800,000 in cash at closing and will receive an additional $200,000 shortly, totaling $1 million in immediate proceeds.

• Significant Future Upside

  Kezar is eligible to receive up to $127 million in development, regulatory, and commercial milestone payments, along with single-digit tiered royalties on net sales of products developed from the acquired assets.

• Strategic Focus

  This divestment allows Kezar to concentrate its resources and efforts on its lead clinical program, zetomizomib, which is being evaluated for immune-mediated diseases.

auto_awesomeAnalysis

This agreement provides Kezar Life Sciences with immediate non-dilutive capital and significant future upside from its Sec61-based discovery and development program. By divesting this asset, Kezar can strategically focus its resources on its core zetomizomib program, which is currently in clinical trials for autoimmune hepatitis. The potential for substantial milestone payments and royalties offers a long-term revenue stream without the associated R&D costs, significantly strengthening the company's financial position and strategic clarity.